PDCD1 and neoplasm: Notably, this combined approach demonstrated superior tumor control compared to treatment with anti-PD-1 alone (Fig. 6C, Supplementary Fig. 6), as well as expanded ILC2s in tumors (Fig. 6D, E, Supplementary Fig. 7).